Brokerage firm Goldman Sachs Maintains its rating on bluebird bio Inc(NASDAQ:BLUE). The shares have been rated Buy. The rating by Goldman Sachs was issued on Sep 15, 2016.
bluebird bio Inc (BLUE) made into the market gainers list on Tuesdays trading session with the shares advancing 3.97% or 2.82 points. Due to strong positive momentum, the stock ended at $73.77, which is also near the day’s high of $74.74. The stock began the session at $71.91 and the volume stood at 14,55,760 shares. The 52-week high of the shares is $143.08 and the 52 week low is $35.37. The company has a current market capitalization of $2,742 M and it has 3,71,69,965 shares in outstanding.
bluebird bio Inc(BLUE) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.55M. Analysts had an estimated revenue of $2.20M. Earnings per share were $-1.59.
Several Insider Transactions has been reported to the SEC. On Aug 5, 2016, Eric Sullivan (Principal Accounting Officer) sold 416 shares at $59.00 per share price.Also, On Jul 19, 2016, David Davidson (Chief Medical Officer) sold 1,000 shares at $45.08 per share price.On Jun 16, 2016, Philip D Gregory (Chief Scientific Officer) sold 2,931 shares at $39.52 per share price, according to the Form-4 filing with the securities and exchange commission.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.